Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer

Abstract

The aim of this study was to explore the expression and clinical significance of miR-494 and PTEN (phosphatase and tensin homologue deleted on chromosome ten) in non-small cell lung cancer (NSCLC). Immunohistochemistry for PTEN and in situ hybridization (ISH) for miR-494 were performed in 92 NSCLC tissues and 10 normal lung tissues to detect their expression, and correlation between their expression with clinical characteristics and prognosis was analyzed. The expression of miR-494 was significantly higher in NSCLC than in normal lung tissues (P = 0.004). The positive expression of PTEN protein in the lung carcinoma tissues was significantly lower than that in the normal lung tissues (P = 0.013), while the level of miR-494 expression was negatively correlated with PTEN expression (r = -0.577, P< 0.01). The high positive rate of miR-494 was positively correlated with pathological TNM (p-TNM) staging and lymph node metastasis. The expression of miR-494 was negatively correlated with grade of differentiation. However, the expression of PTEN was positively correlated with grade of differentiation. Patients with over-expression of miR-494 had a shorter overall survival (OS), while the negative group of PTEN was correlated with poor OS. MiR-494 over-expression and low PTEN expression are closely related to tumor p-TNM staging and lymph node metastasis, differentiation, and OS. Combined detection of PTEN and miR-494 can aid in determining malignancy degree and the prognosis of patients with NSCLC. MiR-494 may be served as a novel prognostic factor and may lead to new treatment strategies for NSCLC.

microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer

“…The expression of miR-494 was negatively associated with the grade of differentiation. In addition, patients with upregulation of miR-494 had a shorter overall survival rate (24). Overexpression of miR-494 improved angiogenesis in NSCLC.…”

“…It has been demonstrated that the expression of miR-494 is altered in several types of human cancer; it is upregulated in the cancer tissues of hepatocellular carcinoma (22), colorectal (23) and non-small-cell lung cancer (24), while it is downregulated in various types of human cancer, including gastric carcinoma (25), prostate cancer (26), esophageal squamous cell carcinoma (ESCC) (27), oral cancer (28), breast cancer (29), pancreatic cancer (30), chondrosarcoma (31) and cervical cancer (32). These conflicting studies indicate that the expression of miR-494 in cancers has tissue specificity.…”

MiRNA expression changes in arsenic-induced skin cancer in vitro and in vivo.

“…Contrary to our finding of it being suppressed in BCC relative to SCC and HK, miR-494 is induced in several cancers (malignant breast cancer, esophageal squamous cell carcinoma, gastric carcinoma, oral cancer, ovarian cancer and pancreatic cancer) (148)(149)(150)(151)(152)(153)(154)(155)(156)(157). Rather than inferring its suppression in BCC, perhaps it is induced early in the transformation of keratinocytes to SCC.…”

Upregulated mrna expression of mtor in surgically resected early stage non-small cell lung carcinoma: a potential molecular targeted therapy

“…On the other hand, a previous study has failed to find association between the mRNA expression level of mTOR gene and pathologic type [16]. Similarly, another study showed that the mRNA expression of the mTOR gene tended to increase in patients with advanced stage (stage III) NSCLC, however, this elevation did not reach statistical significance (9).…”

“…With regard to mTOR expression, it was reported that there was an up-regulation in the expression level of mTOR in tumor tissue as compared to adjacent-tumor tissue [15]. Similarly, Wang et al showed that mRNA expression levels of mTOR in the tumor tissue were outstandingly higher than in adjacent-tumor tissue [16]. Moreover, Liu et al reported that mTOR mRNA expression was elevated in tumor tissue as compared to matched normal tissue [9].…”